Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with capecitabine for advanced ovarian cancer
ChiCTR-OPC-17012186Phase 4Recruiting
- Sponsor
- Hefei Second People's Hospital
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and capecitabine in ovarian cancer, sponsored by Hefei Second People's Hospital. Primary endpoints: Disease control rate and Objective response rate. Started Aug 2017; status: recruiting.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR-OPC-17012186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012186.